Culver City, CA, United States of America

Hans G Klingemann

This inventor holds 47 USPTO granted patents and 34 published patent applications, plus 5 CIPO patents and 7 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Immunitybio, Inc., Nantkwest Inc., Infinity Sa LLC, as Purchaser Agent. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans G Klingemann. Retrieved from https://idiyas.com/inventor/hans-g-klingemann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47 (Patent Applications = 34)

% Patents Active = 97.9

CIPO Patents = 5 (Patent Applications = 14)

EPO Patents = 7 (Patent Applications = 23)

Average Co-Inventor Count = 2.8

ph-index = 6

Forward Citations = 156(Granted Patents)

Location History:

Winnetka, IL (US) (2011 - 2018)
Culver City, CA (US) (2019 - 2022)
San Diejo, CA (US) (2023)
El Segundo, CA (US) (2023)
Boston, MA (US) (2019 - 2024)
San Diego, CA (US) (2020 - 2024)

Company Filing History:

Infinity Sa LLC, as Purchaser Agent

Institute for Cancer Research

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptor

NK Cells

Tumoricidal Compositions

Genetically Modified Cells

Cancer Treatment

PD-L1 Elimination

Cytotoxicity Assays

Immune Enhancement

Antimicrobial Methods

High Affinity NK Cells

Cancer Vaccines

Cellular Immunotherapies

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653874 - Nant cancer vaccine (2026-06-16),

2. 12584138 - QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIES (2026-03-24),

3. 12540170 - CHEMOKINE RESPONSIVE ACTIVATED NATURAL KILLER CELLS WITH SECONDARY HOMING ACTIVATION FOR VERIFIED TARGETS (2026-02-03),

4. 12516093 - RECOMBINANT erIL-15 NK CELLS (2026-01-06),

5. 12498363 - COMBINED INVASION AND CYTOTOXICITY ASSAY USING CHEMOKINE SECRETING TARGET CELLS (2025-12-16),

6. 12492377 - MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC (2025-12-09),

7. 12473348 - ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS (2025-11-18),

8. 12473347 - ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS (2025-11-18),

9. 12435122 - Fc-epsilon CAR (2025-10-07),

10. 12403178 - Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) (2025-09-02),

11. 12384852 - Genetically modified NK-92 cells having a safety switch (2025-08-12),

12. 12378300 - Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells (2025-08-05),

13. 12365874 - Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors (2025-07-22),

14. 12180283 - Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells (2024-12-31),

15. 12109238 - Chimeric antigen receptor-modified NK-92 cells (2024-10-08),

Title: Insights into the Innovations of Hans G. Klingemann

Introduction

Hans G. Klingemann, based in Culver City, California, is a notable inventor with a portfolio comprising 34 patents. His innovative contributions to the field of chimeric antigen receptor (CAR) therapies, particularly in the development of recombinant NK-92 cells, have significantly advanced cancer treatment methodologies.

Latest Patents

Among his latest patents, Klingemann has developed the "Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells." This invention relates to recombinant NK cells that express an Anti-B7-H4 CAR, featuring an intracellular domain of FcεRIγ. One of the standout features of this CAR construct is its prolonged expression duration and cytotoxic efficacy over time. Additionally, it can be expressed from RNA and DNA, using a tricistronic construct that also encodes CD16 and a cytokine for autocrine growth support. These constructs allow for high levels of transfection and expression of recombinant proteins, offering a convenient selection marker for efficient NK/NK-92 cell production.

Another significant patent pertains to "Chimeric antigen receptor-modified NK-92 cells," which outlines NK-92 cells expressing a CAR with an intracellular domain of FcεRIγ. The methods described in this patent pertain to treating patients with cancer or viral infections through the administration of NK-92-CAR cells.

Career Highlights

Klingemann has been associated with leading companies in the biotechnology sector, including ImmunityBio, Inc. and NantKwest, Inc. His work in these organizations has been instrumental in advancing cell therapy treatments, particularly in the area of immunotherapy.

Collaborations

Throughout his career, Hans G. Klingemann has collaborated with prominent figures in the field, including Laurent H. Boissel and Barry J. Simon. These partnerships have fostered groundbreaking developments in NK cell research and their applications in therapeutic settings.

Conclusion

Hans G. Klingemann's contributions to the field of immunotherapy through his innovative patents on CAR-modified NK-92 cells reflect his significant impact on advancing treatment options for cancer and viral infections. His collaborations and career achievements continue to inspire progress within the biotechnological landscape.

Profile summary based on public USPTO records.